RedHill Biopharma sells 70% Talicia stake for $18M

The Ferring agreement pairs exclusive rights for two products with a $12 million upfront payment, royalties and contingent amounts.

Rhea-AI Filing Summary

RedHill Biopharma Ltd. completed the sale of its 70% interest in Talicia Holdings Inc. to a subsidiary of Apotex Health Corp. on August 27, 2026, receiving an upfront $18.0 million upon completion and up to an additional $35.0 million in potential payments based on worldwide net sales milestones. A RedHill subsidiary also entered a transition services agreement with Apotex.

On August 28, 2026, a RedHill subsidiary entered a License and Commercial Supply Agreement with Ferring Pharmaceuticals for exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq. RedHill paid $12 million upfront, agreed to tiered royalties and potential sales milestone and other contingent payments, and acquired existing Rebyota inventory under deferred payment terms. RedHill believes its stockholders’ equity exceeded $5 million as of September 30, 2026, following these transactions and other third-quarter movements.

1 point · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Talicia sale delivered $18.0 million upfront, with up to $35.0 million in sales milestones. 6.2× market cap

Negative

• None.

Key Figures

Upfront payment received for Talicia interest: $18.0 million Potential Talicia sales milestone payments: Up to $35.0 million Talicia interest sold: 70% +2 more

5 metrics

Upfront payment received for Talicia interest $18.0 million Received upon completion of the sale on August 27, 2026

Potential Talicia sales milestone payments Up to $35.0 million Based on worldwide net sales

Talicia interest sold 70% Interest in Talicia Holdings Inc.

Ferring agreement upfront payment $12 million Paid by RedHill

Stockholders’ equity Exceeds $5 million RedHill’s estimate as of September 30, 2026

Key Terms

worldwide net sales milestones, transition services agreement, tiered royalties, deferred payment terms

4 terms

worldwide net sales milestones financial

"potential payments based on worldwide net sales milestones"

transition services agreement technical

"entered a transition services agreement with Apotex"

A transition services agreement is a formal arrangement where one company continues to provide essential services—such as IT, human resources, or accounting—to another company after a business deal or change in ownership. It acts like a temporary bridge, ensuring smooth operations during a transition period. For investors, it provides clarity on how long support will last and helps assess potential costs and stability during the change.

tiered royalties financial

"agreed to tiered royalties"

Tiered royalties are a payment structure where the percentage of earnings paid as royalties changes based on different levels of sales or production. For example, a company might pay a smaller percentage on initial sales and a higher percentage as sales increase beyond certain points. This system encourages higher sales by adjusting payments, making it important for investors to understand how revenue sharing may vary as a product or project grows.

deferred payment terms financial

"inventory under deferred payment terms"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did RedHill receive for selling its Talicia interest?

RedHill received an upfront $18.0 million upon completing the sale of its 70% interest in Talicia Holdings Inc. on August 27, 2026. The sale also provides for up to $35.0 million in potential payments based on worldwide net sales milestones.

What commercialization rights did RedHill obtain from Ferring?

A RedHill subsidiary obtained exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq under an agreement entered on August 28, 2026. RedHill paid $12 million upfront and agreed to tiered royalties and potential sales milestone and other contingent payments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/30/2026 - 04:24 PM Accepted by SEC EDGAR 09/30/2026 - 04:23 PM Learn about SEC filing dates

 UNITED STATES    

SECURITIES AND EXCHANGE COMMISSION  

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer 

Pursuant to Rule 13a-16 or 15d-16  

of the Securities Exchange Act of 1934

For the month of September 2026
Commission File No.: 001-35773

REDHILL BIOPHARMA LTD. 

(Translation of registrant’s name into English)

21 Ha’arba’a Street, Tel Aviv, 6473921, Israel 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

Form 20-F ☒        Form 40-F ☐ 

Recent Transactions and Stockholders' Equity

As previously announced, on August 27, 2026, RedHill Biopharma Ltd. (the “Company”) completed the sale of its 70% interest in Talicia Holdings Inc. (“THI”) to a subsidiary of Apotex Health Corp. (“Apotex”) for an upfront payment of $18.0 million, which was received upon completion of the transaction, and up to an additional $35.0 million in potential payments based on worldwide net sales milestones. In connection with the transaction, the Company, through a subsidiary, also entered into a transition services agreement with Apotex.

On August 28, 2026, the Company, through a subsidiary, entered into a License and Commercial Supply Agreement with Ferring Pharmaceuticals (“Ferring”) for exclusive global commercialization rights to Rebyota® and exclusive U.S. commercialization rights to Clenpiq®. The Company made an upfront payment of $12 million, agreed to pay tiered royalties and potential sales milestone and other contingent payments, and acquired existing Rebyota® inventory under deferred payment terms.

As a result of the transactions described above and other movements during the third quarter, as of September 30, 2026, the Company believes its stockholders' equity exceeds $5 million.

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327), on March 25, 2025 (File No. 333-286082) and on January 22, 2026 (File No. 333-292879), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), October 13, 2023 (File No. 333-274957), as amended, on August 9, 2024 (File No. 333-281417) and on July 2, 2026 (File No. 333-297223).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

September 30, 2026 REDHILL BIOPHARMA LTD.   By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer